Structure Therapeutics surged over 30% pre-market after reporting strong topline results for its weight-loss pill, aleniglipron. The Phase 2b ACCESS study showed 11.3% mean weight loss at 36 weeks, while ACCESS II recorded up to 15.3%. Citing meaningful and dose-dependent results with a favourable safety profile, the company said the drug will advance to Phase 3 trials.